271 related articles for article (PubMed ID: 17965442)
1. Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation.
Vergunst CE; Gerlag DM; Dinant H; Schulz L; Vinkenoog M; Smeets TJ; Sanders ME; Reedquist KA; Tak PP
Rheumatology (Oxford); 2007 Dec; 46(12):1773-8. PubMed ID: 17965442
[TBL] [Abstract][Full Text] [Related]
2. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis.
Gerlag DM; Haringman JJ; Smeets TJ; Zwinderman AH; Kraan MC; Laud PJ; Morgan S; Nash AF; Tak PP
Arthritis Rheum; 2004 Dec; 50(12):3783-91. PubMed ID: 15593225
[TBL] [Abstract][Full Text] [Related]
3. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial.
Vergunst CE; Gerlag DM; Lopatinskaya L; Klareskog L; Smith MD; van den Bosch F; Dinant HJ; Lee Y; Wyant T; Jacobson EW; Baeten D; Tak PP
Arthritis Rheum; 2008 Jul; 58(7):1931-9. PubMed ID: 18576354
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study.
Boumans MJ; Houbiers JG; Verschueren P; Ishikura H; Westhovens R; Brouwer E; Rojkovich B; Kelly S; den Adel M; Isaacs J; Jacobs H; Gomez-Reino J; Holtkamp GM; Hastings A; Gerlag DM; Tak PP
Ann Rheum Dis; 2012 Feb; 71(2):180-5. PubMed ID: 21917822
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.
Haringman JJ; Gerlag DM; Smeets TJ; Baeten D; van den Bosch F; Bresnihan B; Breedveld FC; Dinant HJ; Legay F; Gram H; Loetscher P; Schmouder R; Woodworth T; Tak PP
Arthritis Rheum; 2006 Aug; 54(8):2387-92. PubMed ID: 16869001
[TBL] [Abstract][Full Text] [Related]
6. Expression of C5aR (CD88) of synoviocytes isolated from patients with rheumatoid arthritis and osteoarthritis.
Yuan G; Wei J; Zhou J; Hu H; Tang Z; Zhang G
Chin Med J (Engl); 2003 Sep; 116(9):1408-12. PubMed ID: 14527377
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
Ogrendik M
Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134
[TBL] [Abstract][Full Text] [Related]
8. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
van der Pouw Kraan TC; Wijbrandts CA; van Baarsen LG; Rustenburg F; Baggen JM; Verweij CL; Tak PP
Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
[TBL] [Abstract][Full Text] [Related]
9. Effects of clarithromycin in patients with active rheumatoid arthritis.
Ogrendik M
Curr Med Res Opin; 2007 Mar; 23(3):515-22. PubMed ID: 17355733
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats.
Iyer A; Woodruff TM; Wu MC; Stylianou C; Reid RC; Fairlie DP; Taylor SM; Brown L
J Cardiovasc Pharmacol; 2011 Nov; 58(5):479-86. PubMed ID: 21753735
[TBL] [Abstract][Full Text] [Related]
11. Etanercept reduces synovitis as measured by magnetic resonance imaging in patients with active rheumatoid arthritis after only 6 weeks.
Lisbona MP; Maymo J; Perich J; Almirall M; Pérez-García C; Carbonell J
J Rheumatol; 2008 Mar; 35(3):394-7. PubMed ID: 18203329
[TBL] [Abstract][Full Text] [Related]
12. Dynamic T cell receptor clonotype changes in synovial tissue of patients with early rheumatoid arthritis: effects of treatment with cyclosporin A (Neoral).
VanderBorght A; De Keyser F; Geusens P; De Backer M; Malaise M; Baeten D; Van den Bosch F; Veys EM; Raus J; Stinissen P
J Rheumatol; 2002 Mar; 29(3):416-26. PubMed ID: 11908552
[TBL] [Abstract][Full Text] [Related]
13. Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial.
Silverman MH; Strand V; Markovits D; Nahir M; Reitblat T; Molad Y; Rosner I; Rozenbaum M; Mader R; Adawi M; Caspi D; Tishler M; Langevitz P; Rubinow A; Friedman J; Green L; Tanay A; Ochaion A; Cohen S; Kerns WD; Cohn I; Fishman-Furman S; Farbstein M; Yehuda SB; Fishman P
J Rheumatol; 2008 Jan; 35(1):41-8. PubMed ID: 18050382
[TBL] [Abstract][Full Text] [Related]
14. Effects of high dose IV pamidronate on disease activity and bone metabolism in patients with active RA: a randomized, double-blind, placebo-controlled trial.
Lodder MC; Van Pelt PA; Lems WF; Kostense PJ; Koks CH; Dijkmans BA
J Rheumatol; 2003 Sep; 30(9):2080-1. PubMed ID: 12966622
[No Abstract] [Full Text] [Related]
15. Histological patterns of synovitis and serum chemokines in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Latosiewicz R; Skowronski J; Cylwik JP; Cylwik B; Chwiecko J
J Rheumatol; 2005 Sep; 32(9):1666-72. PubMed ID: 16142858
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats.
Arumugam TV; Woodruff TM; Stocks SZ; Proctor LM; Pollitt S; Shiels IA; Reid RC; Fairlie DP; Taylor SM
J Hepatol; 2004 Jun; 40(6):934-41. PubMed ID: 15158333
[TBL] [Abstract][Full Text] [Related]
17. The effect of ingestion of ferrous sulfate on the absorption of oral methotrexate in patients with rheumatoid arthritis.
Hamilton SF; Campbell NR; Kara M; Watson J; Connors M
J Rheumatol; 2003 Sep; 30(9):1948-50. PubMed ID: 12966595
[TBL] [Abstract][Full Text] [Related]
18. C5a and C5aR are elevated in joints of rheumatoid and psoriatic arthritis patients, and C5aR blockade attenuates leukocyte migration to synovial fluid.
Hornum L; Hansen AJ; Tornehave D; Fjording MS; Colmenero P; Wätjen IF; Søe Nielsen NH; Bliddal H; Bartels EM
PLoS One; 2017; 12(12):e0189017. PubMed ID: 29220376
[TBL] [Abstract][Full Text] [Related]
19. Analysis of serial synovial biopsies in patients with rheumatoid arthritis: description of a control group without clinical improvement after treatment with interleukin 10 or placebo.
Smeets TJ; Kraan MC; Versendaal J; Breedveld FC; Tak PP
J Rheumatol; 1999 Oct; 26(10):2089-93. PubMed ID: 10529122
[TBL] [Abstract][Full Text] [Related]
20. Treatment with anti-C5aR mAb leads to early-onset clinical and mechanistic effects in the murine delayed-type hypersensitivity arthritis model.
Atkinson SM; Nansen A; Usher PA; Sondergaard BC; Mackay CR; Friedrichsen B; Chang CC; Tang R; Skov S; Haase C; Hornum L
Autoimmunity; 2015; 48(7):460-70. PubMed ID: 25915570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
